AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

Core Insights - AbbVie and EvolveImmune Therapeutics have announced a collaboration to develop multispecific therapeutic antibodies for cancer treatment, leveraging EvolveImmune's proprietary T-cell engager platform [1][3] - The partnership aims to address therapeutic challenges in both solid and hematologic malignancies by enhancing T-cell functionality and overcoming cancer cell resistance [2][3] Financial Terms - EvolveImmune will receive $65 million in upfront fees and equity investment from AbbVie, with potential for up to $1.4 billion in option fees and milestones, along with tiered royalty payments on net sales [3] Company Profiles - AbbVie is focused on advancing cancer treatment through innovative therapies and has a dynamic pipeline targeting various cancer types, including blood cancers and solid tumors [5][6] - EvolveImmune is developing first-in-category biotherapeutics aimed at overcoming cancer-driven immunodeficiency, with first-in-human clinical trials expected in 2025 [7]